USING A SINGLE drug to block the renin-angiotensin-aldosterone system (RAAS) may be just as effective as using two drugs at decreasing albuminuria in hypertensive patients with microalbuminuria and elevated cardiovascular risks, data suggest. Dual RAAS blockade achieves greater BP reductions, however.

BP-LOWERING treatment with perindopril decreases the likelihood of major vascular events and stroke in CKD patients with cerebrovascular disease.

STATIN USE is associated with higher rates of BP control, according to researchers.

BLOCKING THE renin-angiotensin-aldosterone system (RAAS) with one drug may be just as effective as using two drugs at decreasing albuminuria in hypertensive patients with microalbuminuria and elevated cardiovascular risks, data suggest. Dual RAAS blockade achieves greater BP reductions, however.

CHICAGO—At least three of every four high-risk hypertensive patients started on single-tablet, fixed-dose, dual-mechanism therapy achieve the recommended target BP of less than 140/90 mm Hg after 18 months, according to preliminary results of an ongoing global trial.

CHICAGO—A survey of general pediatricians showed that 84% of them refer more than two thirds of their adolescent hypertensives to either a nephrologist or cardiologist, researchers reported here at the 22nd Annual Meeting of the American Society of Hypertension.

CHICAGO—A novel beta blocker under FDA review controls BP long term without the adverse effects associated with first-generation beta blockers, according to data presented here at the 22nd Annual Scientific Meeting of the American Society of Hypertension.

CHICAGO—Telmisartan (Micardis HCT), a novel angiotensin receptor blocker (ARB), and the older ARB losartan have similar BP-lowering efficacy in hypertensive patients with diabetic nephropathy, but treatment with the new agent is associated with larger reductions in proteinuria, new findings show.

CHICAGO—Hypertensive patients seem to be ignoring a government-backed diet with proven BP-lowering efficacy, researchers said here at the 22nd Annual Scientific Meeting of the American Society of Hypertension.

CHICAGO—Hypertensive patients basically understand the link between high BP and cardiovascular risk, but wide misconceptions persist, according to data released at the 22nd Annual Scientific Meeting of the American Society of Hypertension.